Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 80.44 | 63.42 | 91.99 | 77.98 | - |
Total Expenses | 78.89 | 98.83 | 115.88 | 86.97 | - |
Profit Before Tax | -19.57 | -38.37 | -23.90 | -8.99 | - |
Profit After Tax | -19.59 | -31.05 | -19.31 | -19.38 | - |
Operating Profit after Depreciation | 2.40 | -33.23 | -20.80 | -5.89 | - |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 13.67 | 15.01 | 110.01 | 107.71 | - |
Total Non Current Assets | 59.40 | 81.99 | 134.73 | 114.72 | - |
Total Current Assets | 31.05 | 27.61 | 61.18 | 47.36 | - |
TOTAL ASSETS | 90.45 | 109.60 | 195.91 | 162.08 | - |
Total Shareholder's Fund | 65.59 | 73.95 | 87.49 | 79.15 | - |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | -9.68 | -14.49 | -37.44 | 4.46 | - |
Net Cash used in Investing Activities | 0.18 | 0.49 | -24.91 | -5.13 | - |
Net Cash used in Financing Activities | 9.60 | 11.41 | 64.07 | 1.16 | - |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 80.44 | 55.65 | 77.91 | 78.23 | 70.09 |
Total Expenses | 78.89 | 63.84 | 77.25 | 86.67 | 83.61 |
Profit Before Tax | 1.55 | -8.18 | 0.67 | -8.44 | -13.51 |
Profit After Tax | 1.53 | -8.18 | 0.67 | -15.59 | -24.38 |
Operating Profit after Depreciation | 2.40 | -7.42 | 1.34 | -5.19 | -10.16 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 13.67 | 15.01 | 15.14 | 14.98 | 113.13 |
Total Non Current Assets | 63.34 | 64.82 | 66.42 | 67.65 | 119.95 |
Total Current Assets | 31.05 | 27.61 | 37.04 | 25.34 | 37.92 |
TOTAL ASSETS | 94.39 | 92.42 | 103.45 | 93 | 157.86 |
Total Shareholder's Fund | 69.53 | 56.78 | 65 | 64.21 | 98.42 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | -9.68 | 0.55 | 3.12 | -0.90 | -9.39 |
Net Cash used in Investing Activities | 0.18 | -0.40 | 1.12 | -0.74 | -2.33 |
Net Cash used in Financing Activities | 9.60 | -0.21 | -4.23 | 1.31 | 9.61 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 38.45 | 20.79 | 17.93 | 17.72 | 21.75 |
Total Expenses | 41.87 | 24.20 | 19.85 | 27.25 | 25.12 |
Profit Before Tax | -4.55 | -3.96 | -2.41 | -9.61 | -3.85 |
Profit After Tax | -4.57 | -3.96 | -2.41 | -9.61 | -3.88 |
Operating Profit after Depreciation | -3.32 | -3.21 | -1.85 | -8.88 | -3.21 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 38.45 | 20.79 | 17.93 | 17.72 | 21.75 |
Total Expenses | 36.60 | 19.28 | 17.65 | 17.34 | 20.66 |
Profit Before Tax | 0.72 | 0.96 | -0.21 | 0.30 | 0.61 |
Profit After Tax | 0.72 | 0.96 | -0.21 | 0.30 | 0.58 |
Operating Profit after Depreciation | 1.95 | 1.71 | 0.35 | 1.03 | 1.25 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Brooks Laboratories Ltd | ₹117.40 | ₹308.14 |
Sun Pharmaceuticals Industries Ltd | ₹1,613.65 | ₹3,87,168.69 |
Divis Laboratories Ltd | ₹5,725.20 | ₹1,51,986.07 |
Cipla Ltd | ₹1,463.25 | ₹1,18,174.12 |
Torrent Pharmaceuticals Ltd | ₹3,028.40 | ₹1,02,490.21 |
Mankind Pharma Ltd | ₹2,337.05 | ₹96,421.67 |
On 13 February 2025
11 Feb 2025, 01:40 pm
On 11 January 2025
21 Dec 2024, 09:53 am
On 11 December 2024
09 Dec 2024, 09:31 am
On 9 November 2024
08 Nov 2024, 08:35 pm
On 19 September 2024
03 Sep 2024, 05:24 pm